Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elan’s Q2 loss narrows
The company reported total revenue of $245.6 million for the second quarter of 2008, an increase of 30% compared to total revenue of $188.5 million for the corresponding
The company reported total revenue of $245.6 million for the second quarter of 2008, an increase of 30% compared to total revenue of $188.5 million for the corresponding
Based on recent communications with the FDA, Duska believes that the proposed single, prospective, placebo-controlled, and randomized trial in patients presenting to the emergency room with paroxysmal supraventricular
Following the FDA’s ‘safe to proceed’ letter for the 18F-ML-10 IND, NST will expand its neurovascular disorders and cancer clinical programs into the US. The first protocol already
The company has reported net sales of $2.02 billion, including sales from divested businesses of $19 million. Worldwide sales of the company’s CRM products for the second quarter
The company posted a net income of $207 million in the second quarter of 2008, an increase of 11% compared to $186 million in the second quarter of
The company posted net sales of $893.74 million in the first quarter of fiscal 2009, an increase of 6.1% compared to $842.61 million reported for the corresponding period
The company attributed the lower second quarter earnings to the acquisition of biotech group Organon BioSciences. The company posted net sales of $4.9 billion in the second quarter
Worldwide sales were $6.1 billion in the second quarter of 2008, a decrease of 1% from the second quarter of 2007. For the first six months of 2008,
The intent of the collaboration between the three parties is to jointly conduct further research to discover and develop compounds that target the hepatitis C virus (HCV). The
Depomed’s ProQuin XR is exclusively licensed to Rottapharm|Madaus for Europe and is a once-daily extended-release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections. Antonino